Loncar Cancer Immunotherapy ETF (CNCR) Research
This exchange-traded fund tracks an index primarily consisting of common stock from roughly 30 pharmaceutical or biotechnology companies. These firms are handpicked by the index provider due to their strong emphasis on creating innovative drugs that harness the human body's natural immune defenses to combat cancer. The fund's advisor aims to allocate all, or nearly all, of its capital into the underlying securities and American Depositary Receipts (ADRs) that comprise this benchmark index. A minimum of 80% of the fund's overall holdings will consistently be directed towards these specific index components. Notably, this fund operates as a non-diversified investment vehicle.
Market snapshot
- Symbol
- CNCR
- Price
- $9.02
- Day change
- +1.58%
- Market cap
- $7.0M
- 52-week range
- 7.881-16.27
- Sector
- Financial Services
- Industry
- Asset Management
Peer companies
- Alpha Architect Merlyn.AI Best-of-Breed Core Momentum ETF (BOB)
- Global Beta Smart Income ETF (GBDV)
- iPath Series B Bloomberg Industrial Metals Subindex Total Return ETN (JJM)
- Pacer Salt Low truBeta US Market ETF (LSLT)
- Hartford Multifactor Low Volatility US Equity ETF (LVUS)
- Nuveen Small Cap Select ETF (NSCS)
- Invesco Russell 1000 Value Factor ETF (OVLU)
- Invesco Russell 1000 Yield Factor ETF (OYLD)
Open Loncar Cancer Immunotherapy ETF (CNCR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.